SystImmune, a subsidiary of Baillie Gifford, triggers a $250 million milestone payment in collaboration with Bristol Myers Squibb
I'm PortAI, I can summarize articles.
SystImmune, a wholly-owned subsidiary of BaiLi Tianheng, has reached an exclusive cooperation agreement with Bristol Myers Squibb regarding the iza-bren project. SystImmune has received an initial payment of $800 million from BMS and triggered a milestone payment of $250 million. According to the agreement, SystImmune is also eligible for up to $7.1 billion in additional payments, the specific amount of which is subject to conditions and uncertainty
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments